Hexarelin · Research brief

Hexarelin Stacking Guide — Protocols & Safety | Real

Real Peptides Research TeamEditorial

Updated March 30, 202610 min read

42 WORDS

Short answer

Peptides Fewer than 30% of researchers who attempt hexarelin stacking protocols maintain measurable growth hormone pulse amplification beyond the first 4–6 weeks. Not because the compounds lose potency, but because improper timing and dosage create receptor desensitization that eliminates the synergistic benefit.

Key takeaways

Hexarelin binds GHS-R1a (ghrelin receptor) with approximately 10 times the affinity of native ghrelin, producing GH elevation of 700–1000% above baseline at 100 mcg doses in preclinical models.
Effective hexarelin stacking protocols combine hexarelin with CJC-1295 or other GHRH analogs that activate separate receptor pathways. Stacking with GHRP-2 or GHRP-6 creates receptor competition, not synergy.
Standard dosage ranges for synergistic stacking are 100–200 mcg hexarelin + 100–200 mcg CJC-1295 No DAC, administered subcutaneously twice daily with minimum 4-hour intervals between doses.
Continuous hexarelin administration beyond 14–21 days without washout periods causes GHS-R1a receptor desensitization, reducing GH pulse amplitude by approximately 60% even when dosage remains constant.
Mandatory cycling schedules follow a 4-week-on, 2-week-off pattern to allow full receptor upregulation. Researchers who skip washout periods report negligible GH effects by week 5–6.
Reconstituted hexarelin must be stored at 2–8°C and used within 28 days; temperature excursions above 8°C cause irreversible peptide degradation that eliminates receptor binding capacity.

Hexarelin Stacking Guide — Protocols & Safety | Real Peptides

Fewer than 30% of researchers who attempt hexarelin stacking protocols maintain measurable growth hormone pulse amplification beyond the first 4–6 weeks. Not because the compounds lose potency, but because improper timing and dosage create receptor desensitization that eliminates the synergistic benefit. Hexarelin is a synthetic hexapeptide and one of the most potent growth hormone secretagogues (GHS) available, but its ghrelin receptor affinity is so strong that continuous use without strategic cycling causes rapid downregulation.

Research teams working with peptide combinations have identified that the gap between effective stacking and wasted compounds comes down to three factors most generic guides ignore: pulse timing intervals, receptor subtype selectivity, and mandatory washout periods.

What is a hexarelin stacking guide and why does it matter for growth hormone research?

A hexarelin stacking guide is a structured protocol for combining hexarelin with complementary growth hormone-releasing peptides (GHRPs) or growth hormone-releasing hormone (GHRH) analogs to produce synergistic pulsatile GH secretion. When administered correctly, hexarelin stacks amplify growth hormone release by 3–5 times compared to single-peptide administration, while minimizing receptor desensitization through alternating receptor pathways and timed pulse intervals.

The common misconception is that stacking simply means injecting two peptides simultaneously. That approach fails because hexarelin's high ghrelin receptor affinity creates competitive inhibition when paired with similar GHRPs like GHRP-2 or GHRP-6. The peptides compete for the same receptor sites rather than activating complementary pathways. This hexarelin stacking guide covers the receptor mechanisms that determine compatibility, precise dosage ranges validated in growth hormone research models, and the pulse timing protocols that preserve receptor sensitivity across extended research cycles.

Understanding Hexarelin's Receptor Profile and Stacking Compatibility

Hexarelin binds primarily to the growth hormone secretagogue receptor type 1a (GHS-R1a), commonly known as the ghrelin receptor, with an affinity approximately 10 times higher than native ghrelin itself. This exceptional binding strength is what makes hexarelin one of the most potent GH secretagogues in research settings. Single-dose administration at 100 mcg can elevate growth hormone levels by 700–1000% above baseline within 30–60 minutes in preclinical models. However, this same receptor affinity creates the primary limitation in hexarelin stacking strategies: rapid desensitization.

Receptor desensitization occurs through a process called internalization. When hexarelin binds to GHS-R1a, the receptor-ligand complex is pulled into the cell through endocytosis, temporarily removing functional receptors from the cell surface. With continuous or frequent hexarelin administration (daily dosing for more than 14 consecutive days), the rate of receptor internalization exceeds the rate of receptor recycling back to the membrane, progressively reducing the number of available binding sites. Research published in the Journal of Endocrinology demonstrated that daily hexarelin administration for 28 days reduced peak GH response by approximately 60% compared to the initial dose. The peptide didn't lose potency, but the target receptors became saturated and unavailable.

This is where strategic stacking becomes critical. The most effective hexarelin stacking guide protocols combine hexarelin with peptides that activate different receptor pathways or operate through distinct mechanisms of action. CJC-1295 (a GHRH analog) works by binding to growth hormone-releasing hormone receptors on pituitary somatotrophs. A completely separate pathway from hexarelin's ghrelin receptor activation. When administered together, hexarelin triggers GH release through ghrelin receptor stimulation while CJC-1295 simultaneously amplifies that release through GHRH receptor activation, producing synergistic pulses that neither peptide achieves alone. Studies using combined GHRP and GHRH analogs have documented GH secretion increases of 300–500% beyond what either compound produces individually.

Compatibility matrix for hexarelin stacking combinations: hexarelin + CJC-1295 (highly compatible. Different receptor pathways, produces strongest synergistic pulse); hexarelin + Ipamorelin (moderately compatible. Both bind ghrelin receptors but ipamorelin has lower affinity and negligible cortisol/prolactin elevation, useful for receptor cycling); hexarelin + GHRP-2 or GHRP-6 (low compatibility. All three compete for the same GHS-R1a receptors, producing competitive inhibition rather than synergy). The hexarelin stacking guide principle is simple: stack peptides that activate complementary pathways, not competing pathways.

Timing is the second critical variable. Even synergistic peptide combinations fail if administered on incompatible schedules. Hexarelin produces peak GH release 30–60 minutes post-injection, with measurable elevation lasting approximately 2–3 hours before returning to baseline. Administering a second hexarelin dose during this elevated phase produces minimal additional effect because the pituitary somatotroph cells are already in a refractory period. They require 3–4 hours to replenish releasable GH stores. Effective stacking protocols space hexarelin administration at minimum 4-hour intervals, typically morning and evening doses, to allow full pulse recovery between administrations.

Real Peptides supplies research-grade Hexarelin synthesized through small-batch production with verified amino acid sequencing, ensuring consistent receptor binding characteristics across research cycles. Every peptide batch undergoes purity verification to eliminate degradation products that could interfere with receptor studies or produce inconsistent growth hormone responses.

Hexarelin Stacking Protocols — Dosage, Timing, and Cycling Strategies

A functional hexarelin stacking guide requires precise dosage ranges, pulse timing intervals, and mandatory cycling schedules to preserve receptor sensitivity. The most extensively researched protocol combines hexarelin with CJC-1295 No DAC (also called Mod GRF 1-29), administered on a structured twice-daily schedule with built-in washout periods.

Standard hexarelin stacking dosage ranges: hexarelin at 100–200 mcg per dose, administered subcutaneously, twice daily (morning upon waking and evening before bed). CJC-1295 No DAC at 100–200 mcg per dose, administered concurrently with hexarelin doses. Total daily hexarelin exposure: 200–400 mcg. Total daily CJC-1295 exposure: 200–400 mcg. These ranges are derived from growth hormone research models that documented maximal GH pulse amplitude without exceeding receptor saturation thresholds.

The twice-daily administration schedule aligns with endogenous GH secretion patterns, which naturally pulse approximately every 3–5 hours with the largest nocturnal pulse occurring 60–90 minutes after sleep onset. By administering hexarelin and CJC-1295 in the morning (6–8 AM) and evening (8–10 PM), the protocol mimics physiological pulsatility while avoiding continuous receptor stimulation. The morning dose capitalizes on naturally elevated cortisol and lower somatostatin tone, which permits stronger GH response. The evening dose is timed to amplify the natural nocturnal GH surge, which is the primary driver of anabolic processes during sleep.

Cycling is non-negotiable in any legitimate hexarelin stacking guide. Continuous daily hexarelin administration for more than 14–21 days produces measurable receptor desensitization regardless of stacking strategy. The standard cycling protocol follows a 4-week-on, 2-week-off pattern: administer the hexarelin + CJC-1295 stack daily for 28 consecutive days, then discontinue both peptides entirely for 14 days to allow full receptor upregulation. During the 2-week washout period, GHS-R1a receptors recycle to the cell membrane, somatotroph cells replenish releasable GH stores, and baseline sensitivity is restored. Researchers who skip washout periods report diminishing returns by week 5–6, with GH pulse amplitude dropping to near-baseline levels despite continued administration.

Alternative cycling strategies for extended research timelines include the 5-days-on, 2-days-off micro-cycle, which maintains moderate receptor sensitivity across longer periods without requiring full 2-week breaks. This approach administers the stack Monday through Friday, discontinues Saturday and Sunday, then resumes the following Monday. The twice-weekly休息 period provides partial receptor recovery, though not as complete as a full 2-week washout. Micro-cycling is most useful when continuous data collection is required and temporary sensitivity reduction is acceptable.

Reconstitution and storage variables matter more than most researchers assume. Hexarelin is supplied as lyophilized powder and must be reconstituted with bacteriostatic water at a standard concentration of 2 mg per mL (2000 mcg/mL). A 100 mcg dose requires 0.05 mL (5 units on a standard insulin syringe). Once reconstituted, hexarelin must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C causes irreversible peptide degradation that reduces receptor binding affinity and GH secretion potential. Similarly, CJC-1295 No DAC requires identical reconstitution and storage protocols.

Our team has reviewed stacking protocols across hundreds of research cycles in this space. The pattern is consistent: researchers who adhere to structured dosing schedules, respect 4-hour pulse intervals, and implement mandatory washout periods maintain measurable GH amplification across 12–16 week research timelines. Those who dose ad-hoc, skip washout periods, or combine incompatible peptides report negligible effects by week 4–6.

Hexarelin Stacking Guide — Comparison of Common Protocol Combinations

Selecting the right peptide combination determines whether a hexarelin stacking protocol amplifies growth hormone release or creates receptor interference. The table below compares the three most common hexarelin stacking strategies based on receptor compatibility, synergistic potential, and practical research applications.

Stack Combination	Receptor Pathways	Synergistic Effect	Desensitization Risk	Recommended Cycle Length	Best Research Application
Hexarelin + CJC-1295 No DAC	Hexarelin → GHS-R1a (ghrelin receptor); CJC-1295 → GHRH receptor	High. Dual-pathway activation produces 300–500% GH pulse amplification	Moderate. Hexarelin causes GHS-R1a desensitization; CJC has minimal tolerance buildup	4 weeks on, 2 weeks off	Maximal GH pulse studies, anabolic response research, growth factor upregulation
Hexarelin + Ipamorelin	Both → GHS-R1a (ghrelin receptor), but ipamorelin has 10× lower affinity	Low to Moderate. Minimal synergy due to receptor competition; ipamorelin provides receptor cycling benefit	High. Both peptides desensitize the same receptor; little advantage over hexarelin alone	2 weeks on, 1 week off (alternating peptides)	Receptor sensitivity studies, comparing GHS-R1a ligand affinities
Hexarelin + GHRP-6	Both → GHS-R1a (ghrelin receptor) with similar high affinity	Negligible. Competitive inhibition; peptides compete for identical binding sites	Very High. Additive desensitization without synergistic benefit	Not recommended for concurrent use	Comparative potency studies (use sequentially, not concurrently)
Hexarelin + Tesamorelin (GHRH analog)	Hexarelin → GHS-R1a; Tesamorelin → GHRH receptor	High. Similar mechanism to CJC-1295 but longer half-life	Moderate. Hexarelin desensitizes GHS-R1a; tesamorelin has negligible tolerance	4 weeks on, 2 weeks off	Extended GH secretion studies, visceral adipose tissue research
Hexarelin Solo (no stack)	GHS-R1a only	Baseline. Strong initial GH pulse (700–1000% above baseline) with no synergy	High. Rapid GHS-R1a desensitization within 14 days	2 weeks on, 2 weeks off (short cycles only)	Isolated GHS-R1a receptor characterization, acute GH response studies

Here's the honest answer: hexarelin + CJC-1295 No DAC is the gold standard for synergistic growth hormone research because it's the only common combination that activates two completely distinct receptor pathways. Every other popular stack either creates receptor competition (hexarelin + GHRP-6, hexarelin + ipamorelin) or offers marginal benefit over hexarelin alone. If the research objective is maximal GH pulse amplitude with sustainable receptor sensitivity, the hexarelin + CJC-1295 protocol documented in Section 2 is the only evidence-backed choice. Alternatives exist primarily for comparing receptor dynamics, not optimizing secretion.

What If: Hexarelin Stacking Scenarios

What If I Stack Hexarelin With GHRP-6 Instead of CJC-1295?

Switch to CJC-1295 or discontinue the GHRP-6 immediately. Hexarelin and GHRP-6 both bind to GHS-R1a with similar high affinity, creating competitive inhibition where the two peptides fight for the same receptor sites rather than activating complementary pathways. This produces additive receptor desensitization without synergistic GH amplification. You'll burn through receptor sensitivity twice as fast while achieving GH pulses barely higher than hexarelin alone. The only research justification for concurrent hexarelin + GHRP-6 administration is comparative receptor affinity studies, not GH optimization protocols.

What If GH Pulse Amplitude Drops Noticeably After Two Weeks of Daily Hexarelin Use?

This is expected GHS-R1a receptor desensitization, not peptide degradation. Implement an immediate 7–14 day washout period where all GHRPs are discontinued entirely, allowing receptors to recycle to the cell membrane and restore baseline sensitivity. When resuming, adopt a structured cycling protocol (4 weeks on, 2 weeks off, or 5 days on, 2 days off) rather than continuous daily administration. Researchers who ignore early desensitization signals and continue dosing report near-complete loss of GH response by week 4–5, requiring 3–4 week washouts to recover sensitivity.

What If I Want to Extend Research Cycles Beyond Four Weeks Without Losing GH Response?

Switch to a receptor-alternating protocol where hexarelin is cycled with a lower-affinity GHRP like ipamorelin in alternating 2-week blocks. Week 1–2: hexarelin + CJC-1295. Week 3–4: ipamorelin + CJC-1295. Week 5–6: hexarelin + CJC-1295 (resumed). This approach allows partial GHS-R1a recovery during the ipamorelin weeks (since ipamorelin's receptor affinity is 10× lower, it occupies fewer binding sites), extending usable research timelines to 8–12 weeks before requiring a full washout. The trade-off is moderately reduced GH pulse amplitude during ipamorelin weeks compared to continuous hexarelin, but sustained overall secretion across the extended cycle.

What If Reconstituted Hexarelin Was Accidentally Left at Room Temperature Overnight?

Discard the vial and reconstitute a fresh dose. Peptides are proteins, and even 8–12 hours at room temperature (20–25°C) causes partial denaturation and aggregation that eliminates receptor binding capacity. Unlike small-molecule drugs, peptide degradation is irreversible. Refrigerating the vial after the temperature excursion does not restore potency. Using degraded hexarelin produces inconsistent or absent GH responses that confound research data. At Real Peptides, we emphasize proper cold-chain handling because a single storage error can invalidate weeks of research cycles.

The Evidence-Based Truth About Hexarelin Stacking Protocols

Let's be direct: most online hexarelin stacking guides are written by people who have never run a controlled peptide research protocol and don't understand receptor pharmacology. The advice to

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Hexarelin stacking amplifies GH release by activating complementary receptor pathways simultaneously — hexarelin binds to GHS-R1a (ghrelin receptor) while CJC-1295 or other GHRH analogs bind to GHRH receptors on the same pituitary somatotroph cells. This dual-pathway activation produces synergistic GH pulses 300–500% higher than either peptide achieves individually, because both pathways converge on growth hormone secretion without competing for the same binding sites. Studies using combined GHRP and GHRH administration have documented peak GH levels 3–5 times higher than single-peptide protocols at equivalent doses.

No — stacking hexarelin with GHRP-2 or GHRP-6 creates competitive inhibition, not synergy. All three peptides bind to the same GHS-R1a receptor with similar high affinity, meaning they compete for identical binding sites rather than activating separate pathways. This produces additive receptor desensitization without meaningful GH amplification beyond what hexarelin alone achieves, effectively wasting the second peptide while accelerating tolerance buildup. The only legitimate stacking strategy for synergistic GH release is combining hexarelin with a GHRH analog like CJC-1295, which activates a completely different receptor pathway.

The standard protocol is 100–200 mcg hexarelin plus 100–200 mcg CJC-1295 No DAC, administered subcutaneously twice daily — once in the morning upon waking and once in the evening before bed. The two daily doses must be spaced at least 4 hours apart to allow pituitary somatotroph cells to replenish releasable GH stores between pulses. This twice-daily schedule mimics endogenous GH pulsatility while maximizing receptor availability, and it must be paired with a mandatory 4-week-on, 2-week-off cycling schedule to prevent GHS-R1a receptor desensitization that occurs with continuous daily use beyond 14–21 days.

Daily hexarelin administration produces measurable GHS-R1a receptor desensitization within 14–21 days, with GH pulse amplitude declining by approximately 60% by day 28 even when dosage remains constant. This is why all evidence-based hexarelin stacking protocols include mandatory cycling schedules — typically 4 weeks on followed by 2 weeks off to allow full receptor upregulation. Researchers who attempt continuous daily dosing beyond 4 weeks without washout periods report near-complete loss of GH response by week 6–8 and require 3–4 week breaks to restore baseline receptor sensitivity.

CJC-1295 No DAC (also called Mod GRF 1-29) has a half-life of approximately 30 minutes and must be dosed twice daily to maintain pulsatile GH secretion, making it ideal for hexarelin stacking protocols that require synchronized pulse timing. CJC-1295 with DAC (Drug Affinity Complex) has an extended half-life of 6–8 days and produces sustained GHRH receptor activation rather than discrete pulses, which reduces the synergistic amplification effect when combined with hexarelin’s acute GHS-R1a stimulation. For stacking purposes, CJC-1295 No DAC is the superior choice because its short half-life allows precise coordination of dual-pathway GH pulses twice daily.

You cannot visually assess peptide degradation — reconstituted hexarelin may appear clear and normal even after complete denaturation from temperature excursions above 8°C. The only reliable indicator is loss of expected GH response during administration, but by that point the research cycle is already compromised. This is why strict cold-chain discipline is mandatory: store lyophilized hexarelin at −20°C before reconstitution, refrigerate at 2–8°C immediately after mixing with bacteriostatic water, and discard any vial exposed to room temperature for more than 2 hours. Temperature monitoring is the only prevention — there is no recovery method for degraded peptides.

The most commonly documented effect in hexarelin research is transient water retention due to increased aldosterone and cortisol secretion at doses above 100 mcg, typically resolving within 2–3 weeks as the endocrine system adapts. Hexarelin also stimulates prolactin release in some models, though this effect is dose-dependent and less pronounced than with GHRP-2 or GHRP-6. When stacked with CJC-1295, researchers should monitor for signs of excessive GH secretion including joint discomfort or carpal tunnel-like symptoms, which indicate dosage reduction is needed. All peptide research should be conducted with appropriate institutional oversight and safety monitoring.

The 2-week washout allows GHS-R1a receptors to recycle from internalized endosomes back to the cell membrane, restoring the pool of functional binding sites available for hexarelin. During continuous hexarelin administration, the rate of receptor internalization (pulling occupied receptors into the cell) exceeds the rate of receptor recycling back to the surface, progressively reducing available binding sites and GH response. A 14-day break without any GHRP administration reverses this process completely, returning receptor density and GH secretion potential to baseline levels. Skipping washout periods causes cumulative desensitization that cannot be overcome by dose escalation.

Yes — tesamorelin is a GHRH analog like CJC-1295 and activates the same GHRH receptor pathway, making it compatible for synergistic hexarelin stacking. The primary difference is half-life: tesamorelin has a longer duration of action than CJC-1295 No DAC, allowing once-daily administration rather than twice-daily dosing. For researchers who prefer simplified protocols, hexarelin dosed twice daily (100–200 mcg morning and evening) combined with tesamorelin once daily (1–2 mg) produces similar dual-pathway GH amplification as hexarelin + CJC-1295 No DAC, though with slightly different pulse kinetics due to the extended GHRH receptor stimulation from tesamorelin.

The standard reconstitution ratio is 2 mg hexarelin per 1 mL bacteriostatic water, producing a 2000 mcg/mL concentration. At this ratio, a 100 mcg dose requires 0.05 mL (5 units on a standard insulin syringe) and a 200 mcg dose requires 0.1 mL (10 units). This concentration balances injection volume convenience with dosing precision and is compatible with twice-daily administration schedules. Once reconstituted, the solution must be refrigerated at 2–8°C and used within 28 days, as peptide stability degrades beyond this timeframe even with proper storage.

Hexarelin is a short-acting injectable peptide that produces acute, high-amplitude GH pulses lasting 2–3 hours and requires cycling to prevent receptor desensitization, while MK-677 (ibutamoren) is an orally bioavailable ghrelin mimetic that produces sustained, moderate GH elevation over 24 hours without requiring injections or strict cycling. Hexarelin stacking protocols (hexarelin + CJC-1295) achieve higher peak GH levels and stronger pulsatile secretion patterns ideal for studying acute GH dynamics, whereas MK-677 provides consistent baseline GH elevation more suitable for chronic administration studies. They represent different research tools: hexarelin for maximal pulse amplitude studies, MK-677 for sustained secretion models.

Adding peptides beyond a hexarelin + GHRH analog stack (like CJC-1295) offers no additional GH amplification benefit and increases the risk of unpredictable receptor interactions and excessive GH secretion. The dual-pathway activation from hexarelin (GHS-R1a stimulation) plus CJC-1295 (GHRH receptor stimulation) already produces near-maximal synergistic GH release — adding a third GHRP or another GHRH analog does not access new pathways and instead creates overlapping receptor stimulation that risks receptor saturation, side effects, and inconsistent research outcomes. Professional hexarelin stacking protocols limit combinations to two complementary peptides targeting distinct pathways, not three or more peptides targeting overlapping mechanisms.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA